Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.

Khan, Tanzeel; Seddon, Alan M; Dalgleish, Angus G; Khelwatty, Said; Ioannou, Nikolaos; Mudan, Satvinder; Modjtahedi, Helmout

Khan, Tanzeel; Seddon, Alan M; Dalgleish, Angus G; Khelwatty, Said; Ioannou, Nikolaos; Mudan, Satvinder; Modjtahedi, Helmout.

Affiliation

Khan T; School of Life Science, Pharmacy and Chemistry, Kingston University London, Surrey KT1 2EE, UK.
Seddon AM; School of Life Science, Pharmacy and Chemistry, Kingston University London, Surrey KT1 2EE, UK.
Dalgleish AG; St George's Hospital, University of London, London SW17 0QT, UK.
Khelwatty S; School of Life Science, Pharmacy and Chemistry, Kingston University London, Surrey KT1 2EE, UK.
Ioannou N; School of Cancer and Pharmaceutical Sciences, King's College London, London SE5 9NT, UK.
Mudan S; St George's Hospital, University of London, London SW17 0QT, UK.
Modjtahedi H; School of Life Science, Pharmacy and Chemistry, Kingston University London, Surrey KT1 2EE, UK.

Oncol Rep ; 44(6): 2581-2594, 2020 12.

Article in En | MEDLINE | ID: mdl-33125153

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Cyclin-Dependent Kinases/antagonists & inhibitors; Pancreatic Neoplasms/drug therapy; Protein Kinase Inhibitors/pharmacology; Receptors, Growth Factor/antagonists & inhibitors; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cell Cycle/drug effects; Cell Line, Tumor; Cell Movement/drug effects; Cell Proliferation/drug effects; Clinical Trials as Topic; Cyclin-Dependent Kinases/metabolism; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms/pathology; Protein Kinase Inhibitors/therapeutic use; Receptors, Growth Factor/metabolism; Research Design

Key words

pancreatic cancer; targeted therapy; HER family; cyclin-dependent kinases; SRC; STAT3; tyrosine kinase inhibitors; combinational therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptors, Growth Factor / Cyclin-Dependent Kinases / Protein Kinase Inhibitors Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Oncol Rep Year: 2020 Document type: Article

Fulltext

XML

PubMed Links

Search on Google